Zymeworks BC Inc. (ZYME) [Rocket]

Overview

Zymeworks BC Inc. (ZYME)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
02/14/2023	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/06/2023	SC 13G/A	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/14/2022	4	Form 4 - Statement of changes in beneficial ownership of securities:
10/24/2022	15-12G	Form 15-12G - Securities registration termination [Section 12(g)]:
10/21/2022	8-K	Quarterly results
10/19/2022	8-K	Quarterly results
10/18/2022	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
Revenues	26.7	39.0	29.5	53.0	51.8	11.0	24.7
Revenue growth	-31.5%	31.8%	-44.3%	2.4%	370.2%	-55.3%
Cost of goods sold	242.3	226.4	180.8	0.0	41.1	48.9	24.4
Gross profit	-215.6	-187.5	-151.3	53.0	10.6	-37.9	0.3
Gross margin	-808.2%	-481.3%	-512.1%	100.0%	20.5%	-343.9%	1.0%
Research and development	199.8	171.2	117.4	56.9		36.8
General and administrative	42.6	55.2	62.7	29.5	18.6	12.6	5.2
EBITA	-212.8	-183.3	-147.4	-31.6	-6.9	-36.6	-19.7
EBITA margin	-797.8%	-470.6%	-499.0%	-59.6%	-13.3%	-332.6%	-80.1%
Amortization of intangibles	2.8	4.2	3.1	1.8	1.1	0.5	0.2
EBIT	-215.6	-187.5	-150.5	-33.4	-7.9	-37.1	-20.0
EBIT margin	-808.2%	-481.3%	-509.5%	-62.9%	-15.3%	-337.0%	-81.0%
Pre-tax income	-212.4	-180.1	-146.0	-34.4	-10.0	-38.9	-19.1
Income taxes	-0.5	0.4	-0.6	2.2	0.4	0.0	0.0
Tax rate	0.2%		0.4%			0.0%	0.1%
Net income	-211.8	-180.6	-145.4	-36.6	-10.4	-33.8	-19.2
Net margin	-794.0%	-463.5%	-492.3%	-68.9%	-20.1%	-307.1%	-77.8%

Diluted EPS	($4.06)	($3.58)	($3.83)	($1.26)	($0.49)	($2.65)	($1.70)
Shares outstanding (diluted)	52.1	50.4	38.0	29.1	21.3	12.7	11.3

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.